Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zbigniew Nowecki

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Plos One|August 17, 2023
Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC studyAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
The Lancet. Oncology|December 28, 2020
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 studyAntoinette R Tan, Seock-Ah Im, André Mattar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
NPJ Breast Cancer|June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse eventsHope S Rugo, David W Cescon, Peter Schmid, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Plos One|August 17, 2023
Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC studyAnna Borowiec, Patrycja Ozdowska, Magdalena Rosinska, et al.
The Lancet. Oncology|December 28, 2020
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 studyAntoinette R Tan, Seock-Ah Im, André Mattar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE TrialPeter A Fasching, Dennis Slamon, Zbigniew Nowecki, et al.
Lancet (London, England)|December 6, 2020
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortes, David W Cescon, Hope S Rugo, et al.
Breast Cancer Research : BCR|October 7, 2024
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2024
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer StudyMiguel Martín, Elgene Lim, Mariana Chavez-MacGregor, et al.
NPJ Breast Cancer|June 26, 2026
Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse eventsHope S Rugo, David W Cescon, Peter Schmid, et al.
The New England Journal of Medicine|October 30, 2024
Inavolisib-Based Therapy in <i>PIK3CA</i>-Mutated Advanced Breast CancerNicholas C Turner, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The Lancet. Oncology|August 30, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trialMafalda Oliveira, Hope S Rugo, Sacha J Howell, et al.
Pageof 4